Prevalence of diabetic nephropathy and subsequent cardiovascular outcomes: a nationwide study of 74,014 patients with type 2 diabetes

Autor: S Parveen, M M Malmborg, A A Arulmurugananthavadivel, L K Koeber, N C Carlson, C A Andersson, D Z Zahir, M M Malik, E F Fosboel, G G Gislason, M S Schou

Publikováno v: European Heart Journal. 43

Background Nonsteroidal, selective mineralocorticoid receptor antagonists (MRAs) have been shown to reduce cardiovascular events among patients with diabetic nephropathy, a clinical syndrome characterized by persistent albuminuria. However, prior rep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e1d1758713fdb7b9a613002b738e744
https://doi.org/10.1093/eurheartj/ehac544.2409

New-onset type 2 diabetes in heart failure: impact of heart failure and death versus ischemic events – a Danish nationwide cohort study

Autor: Torp-Pedersen Ct, M S Schou, G G Gislason, Bochra Zareini, Lars Koeber, Paul Blanche, C S Selmer, Anders Holt, S L K Kristensen, M L Lamberts, Deepthi Rajan, M.M Malik

Publikováno v: European Heart Journal. 41

Background Development of type 2 diabetes (T2D) is common in patients with heart failure (HF), but knowledge of future cardiovascular events is lacking. Purpose We compared risk of heart failure hospitalization (HFH) or death versus ischemic events i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3052eae1f45a21f0c95d2273341a50c
https://doi.org/10.1093/ehjci/ehaa946.1145

409Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies

Autor: M L Lamberts, C T Pedersen, M E Malik, Lars Koeber, Paul Blanche, M S Schou, Bochra Zareini, C M R Rasmussen, J M McMurray, S L K Kristensen, N S Sattar, G G Gislason, Maria D'Souza, C A Andersson

Publikováno v: European Heart Journal. 40

Background Reflecting recent clinical trial findings, updated type 2 diabetes (T2D) guidelines recommend targeting SGLT2 inhibitors at patients at risk of heart failure (HF)-related events and GLP-1 receptor agonists at those at greater risk of ather

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03165a7731b4bff6576e8e3e6944c9bb
https://doi.org/10.1093/eurheartj/ehz747.0104

Initial Decline (Dip) in Estimatec Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction

Autor: Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, Rudolf A. de Boer, Kevin Damman, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Mark C. Petrie, Piotr Ponikowski, Marc S. Sabatine, Morten Schou, Scott D. Solomon, Subodh Verma, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, Muthiah Vaduganathan, Pardeep S. Jhund, John J.V. McMurray

Publikováno v: Adamson, C, Docherty, K F, Heerspink, H J L, De Boer, R A, Damman, K, Inzucchi, S E, Køber, L, Kosiborod, M N, Martinez, F A, Petrie, M C, Ponikowski, P, Sabatine, M S, Schou, M, Solomon, S D, Verma, S, Bengtsson, O, Langkilde, A M, Sjöstrand, M, Vaduganathan, M, Jhund, P S & McMurray, J J V 2022, ' Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction : Insights From DAPA-HF ', Circulation, vol. 146, no. 6, pp. 438-449 . https://doi.org/10.1161/CIRCULATIONAHA.121.058910
Circulation, 146(6), 438-449. LIPPINCOTT WILLIAMS & WILKINS

Background: In a post hoc analysis, the frequency of occurrence of an early decline (dip) in estimated glomerular filtration rate (eGFR) after initiation of dapagliflozin and its association with outcomes were evaluated in patients with heart failure

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::176f669d5bd8bd85c796904409957b89
https://doi.org/10.1161/circulationaha.121.058910

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF

Autor: Felipe Martinez, Lars Køber, Morten Schou, Pooja Dewan, Rudolf A. de Boer, John J.V. McMurray, Pardeep S. Jhund, Mikaela Sjöstrand, Olof Bengtsson, Masafumi Kitakaze, Piotr Ponikowski, Marc S. Sabatine, Daniel Lindholm, Scott D. Solomon, Anna Maria Langkilde, Kieran F. Docherty, Mikail N. Kosiborod, Subodh Verma, Nathaniel M. Hawkins, Akshay S. Desai, Béla Merkely, Mark C. Petrie, Silvio E. Inzucchi, Jarosław Drożdż

Publikováno v: European Journal of Heart Failure
Dewan, P, Docherty, K F, Bengtsson, O, Boer, R A, Desai, A S, Drozdz, J, Hawkins, N M, Inzucchi, S E, Kitakaze, M, Køber, L, Kosiborod, M N, Langkilde, A M, Lindholm, D, Martinez, F A, Merkely, B, Petrie, M C, Ponikowski, P, Sabatine, M S, Schou, M, Sjöstrand, M, Solomon, S D, Verma, S, Jhund, P S & Mcmurray, J J V 2021, ' Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease : an analysis of DAPA-HF ', European Journal of Heart Failure, vol. 23, no. 4, pp. 632-643 . https://doi.org/10.1002/ejhf.2083
European Journal of Heart Failure, 23(4):ejhf.2083, 632-643. Wiley

Aims Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under‐prescription of beta‐blocke

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54219025a51c218ef0e4eef7cb0456ce
http://europepmc.org/articles/PMC8247863